Dermira Raises $35M in Series B Financing

Dermira, a Redwood City, California-based development-stage biotechnology company focused on developing and commercializing innovative new therapies in dermatology, raised $35m in Series B financing.

Backers included new investor Maruho Co., Ltd., a Japanese dermatology company, and existing investors Bay City Capital, New Enterprise Associates, and Canaan Partners.

The company intends to use the funds to advance its therapies.

Led by Tom Wiggans, CEO, Dermira has a portfolio of dermatology therapeutics including lemuteporfin, a selective topical photodynamic therapy for acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, and inflammatory skin diseases.



Join the discussion